Deutsche Bank assumed coverage on shares of Davita (NYSE:DVA) in a research note issued to investors on Thursday, January 3rd, MarketBeat Ratings reports. The brokerage issued a buy rating and a $60.00 price target on the stock.
DVA has been the topic of several other reports. Zacks Investment Research upgraded Davita from a hold rating to a buy rating and set a $81.00 price objective on the stock in a research report on Monday, October 8th. Raymond James downgraded Davita from an outperform rating to a market perform rating and set a $63.44 price objective on the stock. in a research report on Sunday, December 2nd. Royal Bank of Canada upped their price objective on Davita from $70.00 to $78.00 and gave the company a sector perform rating in a research report on Thursday, November 8th. UBS Group started coverage on Davita in a research report on Thursday, November 15th. They issued a sell rating and a $64.00 price objective on the stock. Finally, TheStreet downgraded Davita from a b- rating to a c+ rating in a research report on Thursday, November 8th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and four have given a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and a consensus target price of $71.93.
Davita stock opened at $56.07 on Thursday. The company has a current ratio of 1.84, a quick ratio of 1.82 and a debt-to-equity ratio of 2.09. The firm has a market capitalization of $8.95 billion, a price-to-earnings ratio of 16.89, a PEG ratio of 0.54 and a beta of 1.25. Davita has a fifty-two week low of $48.25 and a fifty-two week high of $80.03.
Davita (NYSE:DVA) last posted its earnings results on Wednesday, November 7th. The company reported $0.56 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.89 by ($0.33). Davita had a net margin of 5.39% and a return on equity of 13.87%. The firm had revenue of $2.85 billion during the quarter, compared to analyst estimates of $2.93 billion. During the same period last year, the company posted $0.81 EPS. The firm’s revenue for the quarter was up 3.0% on a year-over-year basis. Equities analysts predict that Davita will post 3.56 EPS for the current year.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. OppenheimerFunds Inc. lifted its position in Davita by 4.8% during the third quarter. OppenheimerFunds Inc. now owns 4,263,038 shares of the company’s stock worth $305,361,000 after buying an additional 196,721 shares during the period. FMR LLC lifted its position in Davita by 17.2% during the third quarter. FMR LLC now owns 1,943,730 shares of the company’s stock worth $139,229,000 after buying an additional 285,684 shares during the period. Orbimed Advisors LLC lifted its position in Davita by 8.3% during the second quarter. Orbimed Advisors LLC now owns 1,689,400 shares of the company’s stock worth $117,312,000 after buying an additional 129,800 shares during the period. Pendal Group Ltd purchased a new position in Davita during the third quarter worth about $961,000. Finally, Morgan Stanley lifted its position in Davita by 46.9% during the second quarter. Morgan Stanley now owns 946,208 shares of the company’s stock worth $65,704,000 after buying an additional 302,027 shares during the period. Hedge funds and other institutional investors own 85.66% of the company’s stock.
Davita Company Profile
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Recommended Story: Why is the LIBOR significant?
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.